Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Capricor Therapeutics (CAPR) EBIT Margin: 2011-2025

Historic EBIT Margin for Capricor Therapeutics (CAPR) over the last 13 years, with Sep 2025 value amounting to -389,970.92%.

  • Capricor Therapeutics' EBIT Margin fell 38939568.00% to -389,970.92% in Q3 2025 from the same period last year, while for Sep 2025 it was -231.13%, marking a year-over-year decrease of 10349.00%. This contributed to the annual value of -106.41% for FY2024, which is 1078.00% down from last year.
  • As of Q3 2025, Capricor Therapeutics' EBIT Margin stood at -389,970.92%, which was down 94.88% from -200,103.71% recorded in Q2 2025.
  • Capricor Therapeutics' EBIT Margin's 5-year high stood at -10.60% during Q4 2023, with a 5-year trough of -389,970.92% in Q3 2025.
  • Moreover, its 3-year median value for EBIT Margin was -235.90% (2023), whereas its average is -59,166.44%.
  • As far as peak fluctuations go, Capricor Therapeutics' EBIT Margin spiked by 2,203,595bps in 2021, and later tumbled by 38,939,568bps in 2025.
  • Over the past 5 years, Capricor Therapeutics' EBIT Margin (Quarterly) stood at -3,523.90% in 2021, then skyrocketed by 268,358bps to -840.33% in 2022, then soared by 82,973bps to -10.60% in 2023, then crashed by 1,607bps to -26.67% in 2024, then crashed by 38,939,568bps to -389,970.92% in 2025.
  • Its EBIT Margin stands at -389,970.92% for Q3 2025, versus -200,103.71% for Q2 2025 and -26.67% for Q4 2024.